Lunit

Lunit Share Buybacks

The Share Buybacks of Lunit (328130.KQ) as of Nov 6, 2026 is 112.91 M KRW. In the previous year, Share Buybacks was 200.43 B KRW — a change of -99.94% (lower).

Share Buybacks

112.91 MKRW

YoY

-99.94%

Last updated:

Share Buybacks of Lunit is 2024 112.91 M KRW. Share Buybacks of Lunit was 2023 200.43 B KRW. It decreases by -99.94% lower compared to the previous year.

The Lunit Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2019
1.01 B KRW
Jan 1, 2020
3.05 B KRW
Jan 1, 2021
29.29 B KRW
Jan 1, 2022
2.34 B KRW
Jan 1, 2023
200.43 B KRW
Jan 1, 2024
112.91 M KRW
The Lunit Share Buybacks history
YEARShare BuybacksYoY
112.91 MKRW-99.94%
200.43 BKRW+8,472.27%
2.34 BKRW-92.02%
29.29 BKRW+861.75%
3.05 BKRW+202.34%
1.01 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lunit Stock analysis

What does Lunit do? Lunit Inc is a South Korean company headquartered in Seoul, operating within the Health Care sector. The company has 293 employees and went public on July 21, 2022, with its ticker listed as 328130.KQ and ISIN KR7328130000. Lunit provides software solutions for medical diagnostic imaging services, focusing on the development and supply of AI-powered medical software. Its offerings include cancer diagnostic aid solutions, cancer early detection solutions, and cancer risk prediction solutions. The company's technology leverages artificial intelligence to enhance diagnostic capabilities in healthcare settings. Lunit's website is www.lunit.io, where further information about its services and solutions can be accessed. The company operates in the Health Care industry, specifically targeting medical imaging and AI-driven diagnostic tools. As of the latest available data, Lunit is engaged in the development and commercialization of AI-based medical software, aiming to improve the accuracy and efficiency of cancer-related diagnostics. The firm's IPO date marks its transition to a publicly traded company, reflecting its growth and market position in the healthcare technology space. Lunit's focus on AI applications in medical imaging positions it as a key player in the digital health sector, particularly within the Korean market and beyond. The company's solutions are designed to support healthcare professionals in making more informed diagnostic decisions, potentially reducing the time and resources required for cancer detection and treatment planning. Lunit is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lunit stock

Share Buybacks of Lunit is 112.91 M KRW in 2024.

Share Buybacks of Lunit changed from 200.43 B KRW to 112.91 M KRW, representing a -99.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks Lunit since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Lunit historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Lunit

All Key Metrics — Lunit